Zabel U, Weeger M, La M, Schmidt H H
Department of Pharmacology and Toxicology, Julius Maximilians University, 9 Versbacher St., D-97078 Würzburg, Germany.
Biochem J. 1998 Oct 1;335 ( Pt 1)(Pt 1):51-7. doi: 10.1042/bj3350051.
Soluble guanylate cyclase (sGC), a heterodimeric (alpha/beta) haem protein that converts GTP to the second messenger cGMP, functions as the receptor for nitric oxide (NO) and nitrovasodilator drugs. Three distinct cDNA species of each subunit (alpha1-alpha3, beta1-beta3) have been reported from various species. From human sources, none of these have been expressed as functionally active enzyme. Here we describe the expression of human alpha/beta heterodimeric sGC in Sf9 cells yielding active recombinant enzyme that was stimulated by the nitrovasodilator sodium nitroprusside or the NO-independent activator 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole (YC-1). At the protein level, both alpha and beta subunits were detected in human tissues, suggesting co-expression also in vivo. Moreover, resequencing of the human cDNA clones [originally termed alpha3 and beta3; Giuili, Scholl, Bulle and Guellaen (1992) FEBS Lett. 304, 83-88] revealed several sequencing errors in human alpha3; correction of these eliminated major regions of divergence from rat and bovine alpha1. As human beta3 also displays more than 98% similarity to rat and bovine beta1 at the amino acid level, alpha3 and beta3 represent the human homologues of rat and bovine alpha1 and beta1, and the isoenzyme family is decreased to two isoforms for each subunit (alpha1, alpha2; beta1, beta2). Having access to the human key enzyme of NO signalling will now permit the study of novel sGC-modulating compounds with therapeutic potential.
可溶性鸟苷酸环化酶(sGC)是一种异二聚体(α/β)血红素蛋白,可将GTP转化为第二信使环磷酸鸟苷(cGMP),作为一氧化氮(NO)和硝基血管扩张剂药物的受体发挥作用。已从不同物种中报道了每个亚基的三种不同cDNA种类(α1-α3,β1-β3)。从人类来源来看,这些均未表达为具有功能活性的酶。在此,我们描述了人α/β异二聚体sGC在Sf9细胞中的表达,产生了活性重组酶,该酶受到硝基血管扩张剂硝普钠或不依赖NO的激活剂3-(5'-羟甲基-2'-呋喃基)-1-苄基吲唑(YC-1)的刺激。在蛋白质水平上,在人体组织中检测到了α和β亚基,这表明在体内也存在共表达。此外,对人类cDNA克隆(最初称为α3和β3;Giuili、Scholl、Bulle和Guellaen,1992年,《欧洲生物化学学会联合会快报》304,83-88)的重新测序揭示了人类α3中的几个测序错误;对这些错误的纠正消除了与大鼠和牛α1的主要差异区域。由于人β3在氨基酸水平上与大鼠和牛β1也显示出超过98%的相似性,α3和β3代表大鼠和牛α1和β1的人类同源物,并且每个亚基的同工酶家族减少到两种同工型(α1、α2;β1、β2)。能够获得NO信号传导的人类关键酶现在将允许研究具有治疗潜力的新型sGC调节化合物。